Tyrosyl phosphorylation toggles a Runx1 switch

Genes and Development

Volumn 26, Issue 14, 2012, Pages 1520-1526

  Neel, Benjamin G ^a,b   Speck, Nancy A ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

C Src; Megakaryocyte; RUNX1; Shp2; T cell; Tyrosine phosphorylation

Indexed keywords

PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; TRANSCRIPTION FACTOR RUNX1;

ACUTE LEUKEMIA; ARTICLE; CD8+ T LYMPHOCYTE; GAIN OF FUNCTION MUTATION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LYMPHOCYTE DIFFERENTIATION; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RETICULOCYTE LYSATE; TYROSYL PHOSPHORYLATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; HUMANS; MEGAKARYOCYTES; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84864026132     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.198051.112     Document Type: Article

References (58)

1. Aikawa Y, Nguyen LA, Isono K, Takakura N, Tagata Y, Schmitz ML, Koseki H, Kitabayashi I. 2006. Roles of HIPK1 and HIPK2 in AML1-and p300-dependent transcription, hematopoiesis and blood vessel formation. EMBO J 25: 3955-3965.
2. Bakshi R, Hassan MQ, Pratap J, Lian JB, Montecino MA, van Wijnen AJ, Stein JL, Imbalzano AN, Stein GS. 2010. The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes. J Cell Physiol 225: 569-576.
3. Bernardin F, Friedman AD. 2002. AML1 stimulates G1 to S progression via its transactivation domain. Oncogene 21: 3247-3252.
4. Biggs JR, Peterson LF, Zhang Y, Kraft AS, Zhang DE. 2006. AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphasepromoting complex. Mol Cell Biol 26: 7420-7429.
5. Cai X, Gaudet JJ, Mangan JK, Chen MJ, De Obaldia ME, Oo Z, Ernst P, Speck NA. 2011. Runx1 loss minimally impacts long-term hematopoietic stem cells. PLoS ONE 6: e28430. doi: 10.1371/journal.pone.0028430.
6. Cameron ER, Neil JC. 2004. The Runx genes: Lineage-specific oncogenes and tumor suppressors. Oncogene 23: 4308-4314.
7. Canon J, Banerjee U. 2003. In vivo analysis of a developmental circuit for direct transcriptional activation and repression in the same cell by a Runx protein. Genes Dev 17: 838-843.
8. Challen GA, Goodell MA. 2010. Runx1 isoforms show differential expression patterns during hematopoietic development but have similar functional effects in adult hematopoietic stem cells. Exp Hematol 38: 403-416.
9. Chan RJ, Feng GS. 2007. PTPN11 is the first identified protooncogene that encodes a tyrosine phosphatase. Blood 109: 862-867.
10. Chan G, Kalaitzidis D, Neel BG. 2008. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 27: 179-192.
11. Chan G, Kalaitzidis D, Usenko T, Kutok JL, Yang W, Mohi MG, Neel BG. 2009. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood 113: 4414-4424.
12. Collins A, Littman DR, Taniuchi I. 2009. RUNX proteins in transcription factor networks that regulate T-cell lineage choice. Nat Rev Immunol 9: 106-115.
13. Djuretic IM, Cruz-Guilloty F, Rao A. 2009. Regulation of gene expression in peripheral T cells by Runx transcription factors. Adv Immunol 104: 1-23.
14. Egawa T, Tillman RE, Naoe Y, Taniuchi I, Littman DR. 2007. The role of the Runx transcription factors in thymocyte differentiation and in homeostasis of naive Tcells. J Exp Med 204: 1945-1957.
15. Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. 2003. RUNX1 and GATA-1 coexpression and cooperation in megakaryocyte differentiation. Blood 101: 4333-4341.
16. Flores G, Duan H, Yan H, Nagaraj R, Fu W, Zou Y, Noll M, Banerjee U. 2000. Combinatorial signaling in the specification of unique cell fates. Cell 103: 75-85.
17. Grossmann V, Kern W, Harbich S, Alpermann T, Jeromin S, Schnittger S, Haferlach C, Haferlach T, Kohlmann A. 2011a. Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia. Haematologica 96: 1874-1877.
18. Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, Schnittger S, Kern W, Muller MC, Hochhaus A, et al. 2011b. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 25: 557-560.
19. Growney JD, Shigematsu H, Li Z, Lee BH, Adelsperger J, Rowan R, Curley DP, Kutok JL, Akashi K, Williams IR, et al. 2005. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 106: 494-504.
20. Gu T-L, Goetz TL, Graves BJ, Speck NA. 2000. Autoinhibition and partner proteins, CBFb and Ets-1, modulate DNA binding by CBFa2(AML1). Mol Cell Biol 20: 91-103.
21. Guo H, Friedman AD. 2011. Phosphorylation of RUNX1 by cyclin-dependent kinase reduces direct interaction with HDAC1 and HDAC3. J Biol Chem 286: 208-215.
22. Hernandez-Munain C, Krangel MS. 2002. Distinct roles for c-Myb and core binding factor/polyoma enhancer-binding protein 2 in the assembly and function of a multiprotein complex on the TCRd enhancer in vivo. J Immunol 169: 4362-4369.
23. Huang W, Saberwal G, Horvath E, Zhu C, Lindsey S, Eklund EA. 2006. Leukemia-associated, constitutively active mutants of SHP2 protein tyrosine phosphatase inhibit NF1 transcriptional activation by the interferon consensus sequence binding protein. Mol Cell Biol 26: 6311-6332.
24. Huang H, Yu M, Akie TE, Moran TB, Woo AJ, Tu N, Waldon Z, Lin YY, Steen H, Cantor AB. 2009. Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. Mol Cell Biol 29: 4103-4115.
25. Huang G, Zhao X, Wang L, Elf S, Xu H, Sashida G, Zhang Y, Liu Y, Lee J, Menendez S, et al. 2011. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood 118: 6544-6552.
26. Huang J, Woo AJ, Waldon Z, Schindler Y, Moran TB, Zhu HH, Feng GS, Steen H, Cantor AB. 2012. A Src family kinase-Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation. Genes Dev (this issue). doi: 10.1101/gad.192054.112.
27. Ichikawa M, Asai T, Saito T, Yamamoto G, Seo S, Yamazaki I, Yamagata T, Mitani K, Chiba S, Ogawa S, et al. 2004. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 10: 299-304.
28. Kanno T, Kanno Y, Chen L-F, Ogawa E, Kim W-Y, Ito Y. 1998. Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor a subunit revealed in the presence of the b subunit. Mol Cell Biol 18: 2444-2454.
29. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M. 1998. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J 17: 2994-3004.
30. Levanon D, Goldstein RE, Bernstein Y, Tang H, Goldenberg D, Stifani S, Paroush Z, Groner Y. 1998. Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc Natl Acad Sci 95: 11590-11595.
31. Liu X, Qu CK. 2011. Protein tyrosine phosphatase SHP-2 (PTPN11) in hematopoiesis and leukemogenesis. J Signal Transduct 2011: 195239. doi: 10.1155/2011/195239.
32. Liu X, Sabnis H, Bunting KD, Qu CK. 2012. Molecular targets for the treatment of juvenile myelomonocytic leukemia. Adv Hematol 2012: 308252. doi: 10.1155/2012/308252.
33. Lorsbach RB, Moore J, Ang SO, Sun W, Lenny N, Downing JR. 2004. Role of Runx1 in adult hematopoiesis: Analysis of Runx1-IRES-GFP knock-in mice reveals differential lineage expression. Blood 103: 2522-2529.
34. Mangan JK, Speck NA. 2011. RUNX1 mutations in clonal myeloid disorders: From conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog 16: 77-91.
35. Mazharian A, Ghevaert C, Zhang L, Massberg S, Watson SP. 2011. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood 117: 5198-5206.
36. Mohi MG, Williams IR, Dearolf CR, Chan G, Kutok JL, Cohen S, Morgan K, Boulton C, Shigematsu H, Keilhack H, et al. 2005. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 7: 179-191.
37. Mukai K, Benbarak M, Tachibana M, Nishida K, Karasuyama H, Taniuchi I, Galli SJ. 2012. Critical role of P1-Runx1 in mouse basophil development. Blood doi: 10.1182/blood-2011-12-399113.
38. Neel BG, Chan G, Dhanji S. 2009. SH2 domain-containing proteintyrosine phosphatases. In Handbook of cell signaling, 2nd ed. (ed. RA Bradshaw, EA Dennis), pp. 771-810, Academic Press, Waltham, MA.
39. North TE, Gu T-L, Stacy T, Wang Q, Howard L, Binder M, Mari{dotless}́n-Padilla M, Speck NA. 1999. Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. Development 126: 2563-2575.
40. Perez-Vera P, Montero-Ruiz O, Frias S, Rivera-Luna R, Valladares A, Arenas D, Paredes-Aguilera R, Carnevale A. 2008. Multiple copies of RUNX1: Description of 14 new patients, follow-up, and a review of the literature. Cancer Genet Cytogenet 180: 129-134.
41. Pufall MA, Lee GM, Nelson ML, Kang HS, Velyvis A, Kay LE, McIntosh LP, Graves BJ. 2005. Variable control of Ets-1 DNA binding by multiple phosphates in an unstructured region. Science 309: 142-145.
42. Schubbert S, Lieuw K, Rowe SL, Lee CM, Li X, Loh ML, Clapp DW, Shannon KM. 2005. Functional analysis of leukemiaassociated PTPN11 mutations in primary hematopoietic cells. Blood 106: 311-317.
43. Schubbert S, Shannon K, Bollag G. 2007. Hyperactive Ras in developmental disorders and cancer. Natl Rev 7: 295-308.
44. Song W-J, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, et al. 1999. Haploinsufficiency ofCBFA2 (AML1) causes familial thrombocytopenia with propensity to develop acute myelogenous leukamia (FPD/AML). Nat Genet 23: 166-175.
45. Strom DK, Nip J, Westendorf JJ, Linggi B, Lutterbach B, Downing JR, Lenny N, Hiebert SW. 2000. Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J Biol Chem 275: 3438-3445.
46. Takahashi A, Tsutsumi R, Kikuchi I, Obuse C, Saito Y, Seidi A, Karisch R, Fernandez M, Cho T, Ohnishi N, et al. 2011. SHP2 tyrosine phosphatase converts Parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol Cell 43: 45-56.
47. Tanaka T, Kurokawa M, Ueki K, Tanaka K, Imai Y, Mitani K, Okazaki K, Sagata N, Yazaki Y, Shibata Y, et al. 1996. The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol 16: 3967-3979.
48. Taniuchi I, Osato M, Egawa T, Sunshine JJ, Bae S-C, Komori T, Ito Y, Littman DR. 2002. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 111: 621-633.
49. Wang L, Huang G, Zhao X, Hatlen MA, Vu L, Liu F, Nimer SD. 2009. Post-translational modifications of Runx1 regulate its activity in the cell. Blood Cells Mol Dis 43: 30-34.
50. Wong WF, Kohu K, Chiba T, Sato T, Satake M. 2011. Interplay of transcription factors in T-cell differentiation and function: The role of Runx. Immunology 132: 157-164.
51. Woolf E, Xiao C, Fainaru O, Lotem J, Rosen D, Negreanu V, Bernstein Y, Goldenberg D, Brenner O, Berke G, et al. 2003. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci 100: 7731-7736.
52. Yoshida H, Kitabayashi I. 2008. Chromatin regulation by AML1 complex. Int J Hematol 87: 19-24.
53. Yoshimi M, Goyama S, Kawazu M, Nakagawa M, Ichikawa M, Imai Y, Kumano K, Asai T, Mulloy JC, Kraft AS, et al. 2012. Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. Eur J Immunol 42: 1044-1050.
54. Yu M, Mazor T, Huang H, Huang HT, Kathrein KL, Woo AJ, Chouinard CR, Labadorf A, Akie TE, Moran TB, et al. 2012. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell 45: 330-343.
55. Zelent A, Greaves M, Enver T. 2004. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 23: 4275-4283.
56. Zhang F, Meng G, Strober W. 2008. Interactions among the transcription factors Runx1, RORgt and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat Immunol 9: 1297-1306.
57. Zhang L, Fried FB, Guo H, Friedman AD. 2008. Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation. Blood 111: 1193-1200.
58. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, et al. 2012. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481: 157-163.